New research conducted by scientists at Stanford University reveals that a widely prescribed diabetes medication may offer unexpected health benefits beyond glucose control. According to the findings published in the journal Diabetes, Obesity and Metabolism, adults diagnosed with type 2 diabetes who were already taking metformin before contracting COVID-19 demonstrated a thirty-nine percent lower risk of dying within the year following their infection, compared to patients taking a different class of medication known as DPP-4 inhibitors. To evaluate long-term survival rates, researchers analyzed extensive U.S. medical records covering 53,332 adults aged thirty to eighty-five who tested positive for COVID-19 between October 2021 and November 2023. All analyzed patients had been prescribed either metformin or a DPP-4 inhibitor at least one month prior to their medical diagnosis. Scientists suggest that the protective effects could stem from the drug's ability to regulate a biological pathway influencing blood pressure and fluid balance, as well as earlier indications that metformin can reduce overall inflammation and lower viral levels during an active infection. However, independent medical experts urge caution when interpreting these observational statistics. Specialists point out that patients prescribed metformin are typically younger and generally healthier than those prescribed DPP-4 inhibitors, which are frequently reserved for older individuals or patients suffering from kidney disease and other complex health conditions. Furthermore, while initial data hinted at a potential reduction in long COVID symptoms among metformin users, further statistical testing found no definitive, statistically significant link. These findings align with prior research from the University of Minnesota Medical School, though experts emphasize that large, well-designed randomized clinical trials remain necessary to confirm these therapeutic benefits. Fuente: Fox News
También lo cubren: foxnews.com - Latest & Breaking News on Fox News.
Ver más en NewsToday